



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 16 2002

TECH CENTER 1600/2900

Attorney Docket No.: MCP-0054

Inventors: Jameson et al.

Serial No.: 10/018,314

Filing Date: November 2, 2001

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Title: Structure-Based Design of Compounds that
Inhibit Detrimental Cytotoxic T
Lymphocyte Responses

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202

On this date: May 29, 2002

Kathleen A. Tyrrell

Kathleen A. Tyrrell, Registration No. 38,350

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(~~XX~~) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)


are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: May 29, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

**RECEIVED**

AUG 16 2002

TECH CENTER 1600/2900

Sheet 01 of 04

Form PTO-1449 Modified		Docket No. MCP-0054	Serial No. 10/018,314
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Jameson et al.	
		Filing Date November 2, 2001	Group Not Yet Assigned
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AA	Allan et al., "Cardiac Allograft Vasculopathy Is Abrogated by Anti-CD8 Monoclonal Antibody Therapy", Ann Thorac Surg 1997 64:1019-1025		
AB	Baglia et al., "Fine Mapping of the High Molecular Weight Kininogen Binding Site on Blood Coagulation Factor XI through the Use of Rationally Designed Synthetic Analogs", J. Biol. Chem. 1992 267(6):4247-4252		
AC	Bierer et al., "The CD2 Receptor The Role of CD2 Binding to LFA-3 in Adhesion and Activation", Ann. Rev. Immunol. 1989 7:579-599		
AD	Carpenter et al., "Human saphenous vein allograft bypass grafts:Immune response", Journal of Vascular Surgery 1998 27(3):492-499		
AE	Cheng et al., "Surface topography dependence of biomolecular hydrophobic hydration", Nature 1998 392:696-699		
AF	Choksi et al., "A structure-based approach to designing synthetic CD8 α peptides that can inhibit cytotoxic T-lymphocyte responses", Nature Medicine 1998 4:309-314		
AG	Clackson et al., "Structural and Functional Analysis of the 1:1 Growth Hormone:Receptor Complex Reveals the Molecular Basis for Receptor Affinity", J. Mol. Biol. 1998 277:1111-1128		
AH	Gao et al., "Crystal structure of the complex between human CD8 $\alpha\alpha$ and HLA-A2", Nature 1997 387:630-634		
AI	Grewal et al., "The Role of CD40 Ligand in Costimulation and T-Cell Activation", Immunological Reviews 1996 153:85-106		
EXAMINER		DATE CONSIDERED	

**RECEIVED**

AUG 16 2002

TECH CENTER 1600/2900 Sheet 02 of 04

Form PTO-1449 Modified		Docket No. MCP-0054	Serial No. 10/018,314
List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Applicant Jameson et al.	
		Filing Date November 2, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AJ	Grusby et al., "Mice lacking major histocompatibility complex class I and class II molecules", Proc. Natl. Acad. Sci. USA 1993 90:3913-3917	
	AK	He et al., "Inhibition of Intestinal Allograft Rejection by an Anti-CD8 Monoclonal Antibody Is Not Mediated by Depletion Alone", Transplant Proc. 1998 30:1069-1070	
	AL	Huang et al., "Immunoglobulin Superfamily Proteins: Targets for Medicinal Chemistry Research", Med. Chem. Res. 1997 7(3):137-150	
	AM	Jameson B.A., "Modeling in peptide design", Nature 1989 341:465-466	
	AN	Jameson et al., "A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis", Nature 1994 368:744-746	
	AO	Kern et al., "Structural Basis of CD8 Coreceptor Function Revealed by Crystallographic Analysis of a Murine CD8 α Ectodomain Fragment in Complex with H-2K ^b ", Immunity 1998 9:519-530	
	AP	Lai et al., "Plant Alkaloid Tetrandrine and its Analog Block CD28-Costimulated Activities of Human Peripheral Blood T Cells", Transplantation 1999 68(9):1383-1392	
	AQ	Li et al., "Identification of the CD8 DE Loop as a Surface Functional Epitope", J. Biol. Chem. 1998 273(26): 16442-16445	
	AR	Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation", J. Exp. Med. 1991 173:721-730	
EXAMINER		DATE CONSIDERED	



RECEIVED

AUG 16 2002

TECH CENTER 1600/2900 Sheet 03 of 04

Form PTO-1449 Modified		Docket No. MCP-0054	Serial No. 10/018,314
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Jameson et al.	
U.S. Department of Commerce		Filing Date November 2, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AS	Matzinger P., "The JAM test A simple assay for DNA fragmentation and cell death", J. Immunological Methods 1991 145:185-192	
	AT	McDonnell et al., "Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor", Nature Structure Biology 1996 3:419-425	
	AU	Pardanani et al., "Mutational Destabilization of the Critical Interface Water Cluster in Scapharca Dimeric Hemoglobin: Structural Basis for Altered Allosteric Activity", J. Mol. Biol. 1998 284:729-739	
	AV	Pietrzkowski et al., "Inhibition of Cellular Proliferation by Peptide Analogues of Insulin-like Growth Factor 1 ⁿ ", Cancer Research 1992 52:6447-6451	
	AW	Rabinovitch et al., "Cytokines and Their Roles in Pancreatic Islet β -Cell Destruction and Insulin-Dependent Diabetes Mellitus", Biochemical Pharmacology 1998 55:1139-1149	
	AX	Rukavina et al., "Perforin Expression in Peripheral Blood Lymphocytes in Rejecting and Tolerant Kidney Transplant Recipients ¹ ", Transplantation 1996 61(2):285-291	
	AY	Sato et al., "Bioactive Peptide Design Based on Protein Surface Epitopes", J. Biol. Chem. 1997 272(18):12175-12180	
	AZ	Sham et al., "Novel Azacyclic Ureas That Are Potent Inhibitors of HIV-1 Protease", Biochemical and Biophysical Research Communications 1996 225:436-440	
	BA	Sidorova et al., "Differences in water release for the binding of EcoRI to specific and nonspecific DNA sequences", Proc. Natl. Acad. Sci. USA 1996 93:12272-12277	
EXAMINER		DATE CONSIDERED	



RECEIVED

AUG 16 2002

TECH CENTER 1600/2900

Sheet 04 of 04

Form PTO-1449 Modified		Docket No. MCP-0054	Serial No. 10/018,314
List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Applicant Jameson et al.	
		Filing Date November 2, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BB	Li et al., "Identification of a novel human CD8 surface region involved in MHC class I Binding. 'In:Peptides,. Frontiers of Peptide Science.Proceedings of the Fifteenth American Peptide Symposium. 1997, Editors: Tam et al., Publisher:Kluwer Academic Publishers, Dordrecht, Netherlands, pages 493-494	
	BC	Vossen et al., "Role of Macromolecular Hydration in the Binding of the <i>Escherichia coli</i> Cyclic AMP Receptor to DNA", Biochemistry 1997 36:11640-11647	
	BD	Wong et al., "Tolerance and Latent Cellular Rejection in Long-Term Liver Transplant Recipients", Hepatology 1998 28:443-449	
EXAMINER		DATE CONSIDERED	